Science & Medicine, In the Field

The Race to Measure Aging — And Why It Matters

TIME Magazine's in-depth feature explores the rapidly evolving field of biological age measurement, profiling leading researchers and the technologies — including DNA methylation arrays — that are transforming how clinicians and scientists understand aging. The article highlights the growing clinical demand for validated, physician-grade biomarkers that go beyond chronological age.

This TIME feature validates the clinical demand for epigenetic age measurement. XELGEN's genome-wide DNA methylation platform — built on Illumina EPIC arrays — delivers exactly the validated, physician-grade biological age insights the field is calling for.

With FDA Go-Ahead, a China Biotech Notches a First in Cell Therapy Testing

BioPharma Dive reports on Unixell Therapeutics receiving FDA clearance for an IND application to study its allogeneic, iPSC-derived cell therapy in focal epilepsy patients. This represents a significant expansion of cell therapy indications beyond oncology, signaling the field's growing ambition to address neurological and other complex diseases.

Stem cell therapies for diverse disease indications are set to explode. What the field critically needs is XELGEN's Cell Intelligence platform to ensure cellular changes are continuously monitored, validated, and clinically documented throughout treatment.

FDA Greenlights Life Biosciences' Gene Therapy Study to Rewind the Age of Cells

Endpoints News covers the FDA's clearance of Life Biosciences' IND for a partial epigenetic reprogramming gene therapy. The study aims to demonstrate that Yamanaka factor-based interventions can safely reverse cellular aging markers in humans — a landmark moment for the longevity medicine field and a direct validation of epigenetic biomarkers as clinical endpoints.

Advancements in cell and gene therapy are pushing the boundaries of what's biologically possible. Yet there is a critical gap: the lack of standardized monitoring systems. XELGEN's Cell Intelligence platform provides exactly the epigenetic tracking infrastructure needed to document and validate these cellular age changes in real time.

3 New Venture Funds Collect Nearly $1B for Biotech in US & EU

Fierce Biotech reports on three major new venture capital funds targeting biotech innovation across the US and EU. Andreessen Horowitz's Bio Fund IV, the Penn-BioNTech collaboration fund, and Servier Ventures' new vehicle collectively represent nearly $1 billion in fresh capital seeking precision medicine, cell therapy, and longevity science opportunities.

The surge in biotech venture capital reflects growing investor confidence in precision medicine platforms. XELGEN is positioned at the intersection of epigenomics, regenerative medicine, and clinical diagnostics — exactly the convergence point that top-tier funds are actively seeking to back.

NY Giants Team Doctor: Clinics Offering 'Miracle Injections' Are Selling False Hope

STAT News features Dr. Scott Rodeo, the NY Giants' team physician and a leading orthopedic surgeon, who warns that the regenerative medicine industry is rife with unvalidated treatments being sold to patients at premium prices. His call for rigorous clinical monitoring and validated biomarker endpoints is a direct mandate for the kind of objective, evidence-based platform XELGEN provides.

This is precisely why objective, validated cell therapy screening is essential. XELGEN's Cell Intelligence platform provides the epigenetic monitoring infrastructure that ensures regenerative therapies are not only administered — but rigorously tracked, validated, and proven effective for each individual patient.